me.hartmann99/100
Counter-ion identity and content answered quantitatively, one working day. Nothing unsecured in the consignment.
QYB — ChinaPeptides Co., Ltd. (QYAOBIO)
Shanghai, CN · established 2008. The index holds 236 assay reports across 39 batches and 23 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where QYB sells
ChinaPeptides Co., Ltd. (QYAOBIO) sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit QYB at qyaobiopeptides.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- ChinaPeptides Co., Ltd. (QYAOBIO)
- Short code in this index
- QYB
- Also known as
- QYB · QYB Biotech · ChinaPeptides Co., Ltd. (QYAOBIO)
- Domain
- qyaobiopeptides.com →
- City
- Shanghai
- Region
- Shanghai
- Country
- CN
- Established
- 2008
- First record in index
- 07 Mar 2024
- Most recent record
- 07 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.8%
n=236
Retail, shipped to the buyer
75.8%
n=236
Direct to the laboratory
0.8%
n=236
Median courier leg, direct despatch
suppressed
n=2
n<3 — see individual records
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 35 | 14.8% |
| Retail purchase, shipped to the buyer | 142 | 60.2% |
| Retail purchase via a third-party forwarder | 37 | 15.7% |
| Supplier despatch direct to the laboratory | 2 | 0.8% |
| Laboratory retained-sample archive | 20 | 8.5% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 236 QYB records the index holds, 35 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 18 of the 23 compounds QYB is represented by here — Retatrutide, GHRP-6, BPC-157, GHRP-2, Semaglutide, AOD-9604 and 12 further compounds. Those are the QYB lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents QYB stock held in Poland, with a transit of 4 working days against a quoted 4. Poland is the only regional stock location named anywhere in QYB's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is QYB's own reviewers: 3 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.54%
n=236
Interquartile range
0.63pp
n=236
10th percentile
98.71%
n=236
Pass rate vs index spec
98.3%
n=236
Median recovery vs claim
97.3%
n=131
Median water
4.35%
n=236
Median |mass error|
2.3ppm
n=197
Records carrying a flag
14.4%
n=236
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.56pp
n=28
Index median spread
0.67pp
n=28
Lots tested 3+ times
28
n=39
Across the 28 QYB lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.56 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.04pp
n=39
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
51%
n=39
Divergences beyond 1 pp
0%
n=39
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.51%
n=214
Supplier-supplied median
suppressed
n=2
n<3 — see individual records
Supplier-supplied share of records
0.8%
n=236
Too few records in one or both provenance classes (buyer-sourced n=214, supplier-supplied n=2) to compute a provenance gap for QYB. The index-wide effect is +0.31 pp and applies until measured otherwise.
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of QYB batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
91/100
n=39
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 79% | 25 points | |
| Peptide content stated | 64% | 20 points | |
| Endotoxin stated | 26% | 15 points | |
| Named impurities rather than a total | 69% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| BPC-157 | Tissue-repair | 30 | 99.90 | 99.16 | +0.74 | 98.0 | 100 |
| Retatrutide | Incretin | 28 | 98.47 | 98.37 | +0.09 | 96.5 | 100 |
| GHRP-6 | Growth-hormone | 27 | 99.48 | 99.54 | -0.06 | 99.0 | 96 |
| Tirzepatide | Incretin | 22 | 99.25 | 98.55 | +0.70 | 97.0 | 100 |
| Semaglutide | Incretin | 18 | 99.38 | 98.89 | +0.49 | 97.0 | 100 |
| N-Acetyl Semax Amide | Neuroactive | 14 | 99.72 | 99.35 | +0.37 | 98.5 | 100 |
| Oxytocin | Hypothalamic | 12 | 99.69 | 99.81 | -0.13 | 98.5 | 100 |
| Thymosin α1 | Tissue-repair | 12 | 99.76 | 99.40 | +0.36 | 97.5 | 100 |
| AOD-9604 | Metabolic | 12 | 99.52 | 99.29 | +0.23 | 98.0 | 100 |
| GHRP-2 | Growth-hormone | 10 | 99.05 | 99.28 | -0.23 | 99.0 | 70 |
| Ipamorelin | Growth-hormone | 9 | 99.93 | 99.47 | +0.46 | 99.0 | 100 |
| Humanin (HNG) | Metabolic | 9 | 99.27 | 99.12 | +0.15 | 97.5 | 100 |
| Sermorelin | Growth-hormone | 9 | 99.55 | 99.06 | +0.49 | 98.0 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 5 n=5 | 99.72 | 99.38 | +0.34 | 98.5 | 100 |
| TB-500 | Tissue-repair | 5 n=5 | 99.90 | 99.53 | +0.37 | 98.5 | 100 |
| ARA-290 | Tissue-repair | 3 n=3 | 99.66 | 99.42 | +0.24 | 98.0 | 100 |
| Pemvidutide | Incretin | 2 n=2 | n<3 | 98.25 | — | 96.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 2 n=2 | n<3 | 99.49 | — | 98.5 | 100 |
| Selank | Neuroactive | 2 n=2 | n<3 | 99.59 | — | 99.0 | 100 |
| Melanotan II | Melanocortin-receptor | 2 n=2 | n<3 | 99.42 | — | 98.5 | 100 |
| Liraglutide | Incretin | 1 n=1 | n<3 | 99.00 | — | 97.5 | 100 |
| SS-31 (Elamipretide) | Metabolic | 1 n=1 | n<3 | 99.53 | — | 98.5 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 1 n=1 | n<3 | 99.09 | — | 98.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 1 | 3 | 99.00 | 98.68–99.36 | 0 |
| 2024-Q2 | 4 | 20 | 99.34 | 98.20–99.93 | 1 |
| 2024-Q3 | 2 | 8 | 99.29 | 98.99–99.93 | 1 |
| 2024-Q4 | 2 | 9 | 99.92 | 99.40–99.93 | 4 |
| 2025-Q1 | 3 | 10 | 99.79 | 99.35–99.93 | 0 |
| 2025-Q2 | 4 | 29 | 99.64 | 98.95–99.93 | 2 |
| 2025-Q3 | 4 | 13 | 99.30 | 98.66–99.93 | 4 |
| 2025-Q4 | 6 | 52 | 99.19 | 97.75–99.93 | 12 |
| 2026-Q1 | 6 | 47 | 99.53 | 99.01–99.93 | 4 |
| 2026-Q2 | 4 | 27 | 99.81 | 99.03–99.93 | 3 |
| 2026-Q3 | 3 | 18 | 99.09 | 97.93–99.93 | 3 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 114 | 99.51 | +0.00 | 99.51 |
| PeptideMeter | 45 | 99.40 | -0.05 | 99.45 |
| Medutest | 29 | 99.62 | +0.08 | 99.54 |
| VendorInvestigate | 14 | 99.73 | -0.11 | 99.84 |
| Nordanalyt | 18 | 99.40 | +0.02 | 99.38 |
| Kestrel | 16 | 99.85 | +0.24 | 99.61 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
97.0/ 100570 ratings across the index network
h.nascimento98/100
Documentation complete at first issue. No supplementary request raised. VendorInvestigate report held on file, figures match published.
ce.kjaer97/100
Consistency: 7 lots, purity band under 1.0 points wide. Regional stock held for the lines concerned. Independent verification of individual lots still required.
s.molnar96/100
Peptide content reported separately from chromatographic purity across all 10 certificates held. Vial-to-vial mass variation under 2%.
c.stanescu98/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Identity confirmed by two orthogonal methods.
k.marchetti97/100
Supplementary certificate for a lot released 15 months earlier retrieved from supplier records on request. Identifier matches across vial, certificate and commercial documentation.
mi.villalobos96/100
Published stock status matched availability. Same-day dispatch. Tracking record corresponded to consignment position at every hop. Submitted to the index in full.
sa.ivaturi95/100
Release signed and dated, named individual. Medutest report held on file, figures match published.
v.yildiz100/100
Quoted 5 working days, dispatched on day 3. Subsequent orders placed with the same supplier.
bi.halvorsen96/100
Reconstitution of tirzepatide 10 mg: clear on contact, no haze, no particulate. n=1, declared as n=1.
p.vukovic99/100
Batch record supplied in full on request, attached rather than summarised. Identity confirmed by two orthogonal methods.
e.beaulieu95/100
9 orders, 24 months. No substitution, no reformulation, no post-payment unavailability. Identifier matches across vial, certificate and commercial documentation.
ne.achebe96/100
Fill uniformity: 12 units weighed against declared fill, all within 2%. Research use. Not approved for human administration.
a.malinowski97/100
Transit 4 days from stock held in Poland against a quoted 4. Customs documentation correct at first presentation. No adverse observation.
ad.molnar98/100
Storage condition for the stability statement stated on the certificate. Reorder at 24 months within 0.1 points of the original. n=1, declared as n=1.
n.bruun99/100
Retention time assigned to the principal peak, printed. Quotation held from enquiry through to invoice with no revision and no added handling line. Record covers the lots named. Not generalised.
m.ostergaard95/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Identity confirmed by two orthogonal methods. Independent verification of individual lots still required.
a.mensah96/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Identifier matches across vial, certificate and commercial documentation.
lu.ndiaye100/100
Water content, counter-ion and peptide content all on the first certificate. Mass balance closes on the printed figures.
i.okonkwo97/100
Lot QYB-26-843 submitted to PeptideMeter. Declared 97.6%, reported 98.0%. Delta inside method repeatability. PeptideMeter report held on file, figures match published.
c.molnar98/100
Direct-supply material 98.9%. Intermediary vial, same nominal description, 98.5%. Further submissions on later lots would improve coverage.
b.kimani97/100
Residual-solvent screen included unrequested. Pricing published against lot size on request; the quoted figure was the invoiced figure. Independent verification of individual lots still required.
ha.hartmann95/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Identity confirmed by two orthogonal methods.
ja.cabrera99/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. No excipient. Cake intact. Evidence base adequate for a rating on this criterion.
z.mensah99/100
Labelling printed, lot and date legible on every unit examined. Nothing unsecured in the consignment. Record covers the lots named. Not generalised.
t.vanhecke98/100
Certificate carries a signature and a date from whoever released the batch. Complete against the index minimum data set at first issue. Medutest report held on file, figures match published.
Block 12
Most recent records
Block 13
Contributor annotations on QYB records 468
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on QYB material are below, each linked to the record it sits on.
Endotoxin is a fill-suite property, so it is broadly consistent within a supplier and within a period. That consistency is what makes the gap worth closing on a sample of lots rather than on all of them.
Inorganic residue from a buffer salt carried through the last lyophilisation is invisible on a chromatogram and obvious on an ash determination. It belongs in the residual slot.
Mass, retention and impurity profile all agree on this record. Three independent constraints pointing the same way is the strongest identity evidence the index publishes.
Well inside class limit. Worth noting that the class limits are set by mass rather than globally, because the same ppm is a different number of daltons at 340 and at 4,800.
Area percent assumes unit response factors across every species present. At 99.93 % the assumption barely matters — there is not enough impurity for a response-factor error to move the figure by a tenth.
At 214 nm the amide bond dominates the response, so a peptide impurity is seen roughly in proportion to its size. 99.58 % on this detection is the conservative reading; a 280 nm trace would flatter it.
Column chemistry flatters or punishes a figure like this. A core-shell column at this gradient resolves the close-eluting family that a fully porous 5 µm bed merges, so 99.58 % here is a harder number than the same figure from a coarser column.
99.58 % on PT-141 (Bremelanotide) sits at the top of what this index sees. Read it with the method: PeptideMeter ran a 28 min gradient here, and the compound fingerprint names a mass-identical species that a shorter run folds into the main peak. On this gradient the figure is well founded.
Every annotation the index holds on QYB material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what QYB itself publishes, open qyaobiopeptides.com → alongside.
Block 14
Where to buy QYB
ChinaPeptides Co., Ltd. (QYAOBIO) sells direct from qyaobiopeptides.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the QYB store at qyaobiopeptides.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.